Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Benzinga

Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines

Novartis AG (NYSE:NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension…

Benzinga

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

Key Takeaways: Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialize two core products licensed from Novartis The company currently is not generating any sale, with most of its products in early stages of development By Tina Yip

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria

Novartis AG (NYSE:NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an aim to eliminate these diseases. "Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done," CEO Vas Narasimhan said. Novartis…

Benzinga

FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use

The FDA granted accelerated approval to Novartis AG's (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer.…

Benzinga

Novartis Follows Eli Lilly with $1.4 Billion Gene Editing Pact

Precision BioSciences is developing gene editing tools with several potential advantages over CRISPR.

The Street

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Explained | The Indian patent regime and its clash with the U.S. norms

The U.S. Trade Representative highlighted IP challenges in India in its annual Special 301 report released last month

The Hindu

Firms rejig to survive in lean times

Businesses adopted cost reduction, increased productivity, and emphasised environmental standards to cope with the pandemic and global challenges stemming from the Russia-Ukraine war, panellists told the Forbes Thailand 2022 Forum on Monday.

Bangkok Post

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Reuters

Work on environmental and economic Novartis 'leaving gift' legacy begins

Wetland habitat to be created to enable future inward investment and economic development at pace

Birmingham Post

KTR hardsells Telangana at Davos

Meets top honchos of tech and pharma companies

The Hindu

Buyer of Novartis Grimsby outlines what could be next for 'world-class' pharmaceutical complex

International Process Plants has taken it on under new subsidiary Humber Industrials Ltd - eyeing onshoring of production as a possibility

Birmingham Post

Cancer Coalition Aims to Boost Access to Medicines in Poorer Countries

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries,…

Asharq Al-Awsat

Get all your
news in one place.

100’s of premium titles.
One news app.

Birmingham Post

All Novartis jobs to go as land and process plant sale agreed with international industrial dealer

Slim hopes of a going concern sale of Grimsby site appear to have been dashed - with remaining 212 employees now facing redundancy

Benzinga

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Investors Business Daily

Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis

Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.

Benzinga

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock?

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Upgrades

Tribune News Service

‘Please pay attention’: Scientist flagged heart-pill toxins early on

A scientist at a China-based company that makes crucial ingredients for generic drugs warned a year before the start of a global recall that some blood-pressure pills could become tainted with potentially cancer-causing chemicals, according to court documents.

Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Why Molecular Partners Shares Are Getting Hammered

Molecular Partners AG (NASDAQ: MOLN) shares are trading lower by 36.52% at $8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.

Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

Benzinga

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2,…

Benzinga

Novartis: Q1 Earnings Insights

Novartis (NYSE:NVS) reported its Q1 earnings results on Tuesday, April 26, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.